Journal
IMMUNOTHERAPY
Volume 8, Issue 8, Pages 889-906Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2016-0049
Keywords
autoimmune diseases; foralumab; immune tolerance; immunotherapy; monoclonal CD3 antibodies; otelixizumab; Tregs; teplizumab; Type 1 diabetes; visilizumab
Categories
Funding
- Serono
- Biogen
- Therapix
- Novartis
- Tiziana Life Sciences
- Genzyme
- Teva
- NIH [R01 AI43458]
Ask authors/readers for more resources
The induction of tolerance is a major goal of immunotherapy. Investigations over the last 20 years have shown that anti-CD3 monoclonal antibodies (mAbs) effectively treat autoimmune disease in animal models and have also shown promise in clinical trials. Tolerance induction by anti-CD3 mAbs is related to the induction of Tregs that control pathogenic autoimmune responses. Here, we review preclinical and clinical studies in which intravenous or mucosal administration of anti-CD3 mAbs has been employed and provide an outlook on future developments to enhance the efficacy of this promising therapeutic approach.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available